Corbus Pharmaceuticals Holdings Inc CRBP:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 06/11/21 EDT
2.17quote price arrow up+2.17 (UNCH)
Volume
9,756
Close
2.18UNCH (UNCH)
Volume
904,088
52 week range
0.91 - 9.78

...

Loading . . .
  • Open2.17
  • Day High2.20
  • Day Low2.14
  • Prev Close2.18
  • 52 Week High9.78
  • 52 Week High Date08/31/20
  • 52 Week Low0.91
  • 52 Week Low Date10/30/20

Key Stats

  • Market Cap272.57M
  • Shares Out125.03M
  • 10 Day Average Volume4.20M
  • Dividend-
  • Dividend Yield-
  • Beta1.77
  • YTD % Change74.4

KEY STATS

  • Open2.17
  • Day High2.20
  • Day Low2.14
  • Prev Close2.18
  • 52 Week High9.78
  • 52 Week High Date08/31/20
  • 52 Week Low0.91
  • 52 Week Low Date10/30/20
  • Market Cap272.57M
  • Shares Out125.03M
  • 10 Day Average Volume4.20M
  • Dividend-
  • Dividend Yield-
  • Beta1.77
  • YTD % Change74.4

RATIOS/PROFITABILITY

  • EPS (TTM)-1.18
  • P/E (TTM)-1.85
  • Fwd P/E (NTM)-4.58
  • EBITDA (MRQ)-107.262M
  • ROE (MRQ)-171.05%
  • Revenue (MRQ)2.82M
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-3,460.08%
  • Debt To Equity (MRQ)20.33%

EVENTS

  • Earnings Date08/08/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Corbus Pharmaceuticals Holdings Inc

There is no recent news for this security.

Profile

MORE
Corbus Pharmaceuticals Holdings, Inc. is a Phase-III, clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic...
Alan Holmer J.D.
Chairman
Yuval Cohen Ph.D.
Chief Executive Officer
Sean Moran CPA
Chief Financial Officer
Address
500 RIVER RIDGE DRIVE
Norwood, MA
02062
United States

Top Peers

SYMBOLLASTCHG%CHG
EIGR
Eiger BioPharmaceuticals Inc
8.04-0.04-0.50%
ONCT
Oncternal Therapeutics Inc
5.42-0.04-0.73%
KZR
Kezar Life Sciences Inc
5.64-0.03-0.53%
MRKR
Marker Therapeutics Inc
3.35+0.11+3.40%
KLDO
Kaleido Biosciences Inc
6.75-0.64-8.66%